GI Cancer Immunotherapy Breakthroughs Signal New Treatment Era [Canadian Business Journal (Canada)]
Oncolytics Biotech Inc. - Common Shares (ONCY)
Last oncolytics biotech inc. - common shares earnings: 11/12 04:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.oncolyticsbiotech.com
Company Research
Source: Canadian Business Journal
VANCOUVER, British Columbia, Dec. 12, 2025 (GLOBE NEWSWIRE) —Equity-Insider.comNews Commentary[1][2]Oncolytics Biotech Inc.Agenus Inc.Cardiff Oncology, Inc.Exelixis, Inc.Gilead Sciences, Inc.Analysts project the global immuno-oncology market will climb at a CAGR of 15.7% toward a value of US$416.28 billion by 2034[3]FDA alignment on its pivotal Phase 3 studyFollowing a Type C meeting, the“We now have regulatory clarity to allow us to start a pivotal study and ultimately the chance to bring the first approved immunotherapy treatment option to the pancreatic cancer treatment landscape,” said Jared Kelly, CEO ofThe trial will test three arms: standard chemotherapy (gemcitabine plus nab-paclitaxel) alone, the same chemotherapy with pelareorep, and chemotherapy with both pelareorep and a checkpoint inhibitor. Overall survival serves as the primary goal, with either experimental arm able to independently demonstrate success.“The FDA’s feedback confirms that our design is appropriate to supp
Show less
Read more
Impact Snapshot
Event Time:
ONCY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ONCY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ONCY alerts
High impacting Oncolytics Biotech Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics
ONCY
News
- Pancreatic Cancer Survival Gains Accelerate as Novel Therapies Advance [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- GI Cancer Immunotherapy Breakthroughs Signal New Treatment EraGlobeNewswire
- Oncolytics Biotech (NASDAQ:ONCY) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Oncolytics Biotech® Reschedules Special Meeting of Shareholders to Change Jurisdiction of Incorporation to NevadaBusiness Wire
- THE EFFICIENCY PARADOX: 5 Market Anomalies Trading Below Reality [Canadian Business Journal (Canada)]Canadian Business Journal
ONCY
Earnings
- 11/12/25 - Miss
ONCY
Sec Filings
- 12/10/25 - Form EFFECT
- 12/10/25 - Form 6-K
- 12/9/25 - Form 424B3
- ONCY's page on the SEC website